

【original articles】

1. Harigai M, Fujii T, Sakai R, Igarashi A, Shoji A, Yamaguchi H, Iwasaki K, Makishima M, Yoshida A, Okada N, Yamashita K, and Kawahito Y. Risk of hospitalized infections in older elderly patients with rheumatoid arthritis treated with tocilizumab or other biological/targeted synthetic disease-modifying antirheumatic drugs: Evaluation of data from a Japanese claims database. *Mod Rheumatol*. 2024. 34(2):287-296. doi: 10.1093/mr/road031. PMID: 37039670.
2. Kuwana M, Sugiyama N, Momohara S, Atsumi T, Takei S, Tamura N, Harigai M, Fujii T, Matsuno H, Takeuchi T, Yamamoto K, Takasaki Y, Tanigawa M, Endo Y, Hirose T, Morishima Y, Yoshii N, Mimori T, Takagi M. Six-month safety and effectiveness of tofacitinib in patients with rheumatoid arthritis in Japan: Interim analysis of post-marketing surveillance. *Mod Rheumatol*. 2024. 34(2):272-286. doi: 10.1093/mr/road063. PubMed PMID: 37405710.
3. Fujii T, Murata K, Onizawa H, Onishi A, Tanaka M, Murakami K, Nishitani K, Furu M, Watanabe R, Hashimoto M, Ito H, Fujii T, Mimori T, Morinobu A, Matsuda S. Management and treatment outcomes of rheumatoid arthritis in the era of biologic and targeted synthetic therapies: evaluation of 10-year data from the KURAMA cohort. *Arthritis Res Ther*. 2024;26(1):16. doi: 10.1186/s13075-023-03251-z. PMID: 38195572
4. Abe Y, Fujii T, Miyawaki Y, Sugihara T, Uchida HA, Maejima Y, Watanabe Y, Hashimoto T, Miyamae T, Nakaoka Y, Harigai M, Tamura N. Real-world clinical decisions of physicians in the management of Takayasu arteritis and giant cell arteritis in Japan: A cross-sectional web questionnaire survey. *Mod Rheumatol*. 2024;34(6):1194-1201. doi:10.1093/mr/roae034. PMID: 38590042
5. Katsumata Y, Sada KE, Kameda T, Dobashi H, Kaname S, Tsuboi N, Matsumoto Y, Amano K, Tamura N, Harigai M; Members of the Research Committee of Intractable Vasculitis Syndrome and the Research Committee of Intractable Renal Disease of the Ministry of Health, Labour and Welfare of Japan (Fujii T). Comparison of different ANCA detection methods in a predominantly MPO-ANCA-associated vasculitis cohort. *Immunol Med*. 2024. 48(1):47-57. doi: 10.1080/25785826.2024.2408054. PMID: 39391948.
6. Okamoto N, Atsumi T, Takagi M, Takahashi N, Takeuchi T, Tamura N, Nakajima A, Nakajima A, Fujii T, Matsuno H, Ishii T, Tsujimoto N, Nishikawa A, Minatoya M, Tanaka Y, Kuwana M. Safety of baricitinib in Japanese patients with rheumatoid arthritis in clinical use: 3-year data of all-case post-marketing surveillance study. *Mod Rheumatol*. 2024.35(2):215-224. doi: 10.1093/mr/roae064. PMID: 39119689.
7. Ueno M, Iwata S, Yamagata K, Todoroki Y, Sonomoto K, Miyagawa I, Kubo S, Miyazaki Y, Hiroko Miyata H, Nagayasu A, Kanda R, Aritomi T, Nakayamada S, Tanaka Y. The induction of interleukin-21 receptor expression via enhanced intracellular metabolism in B cells and its relevance to the disease activity in systemic lupus erythematosus. *RMD open*. 2024;10(4):e004567. doi: 10.1136/rmdopen-2024-004567. PMID: 39740932; PMCID: PMC11749818.

【case report】

1. Kawajiri T, Iwata S, Tanaka K, Sonoda T, Nishikawa M, Iwamoto R, Takahashi Y, Kojima F, Fujii T. Granulomatosis with polyangiitis with lacrimal gland enlargement and pancreatic swelling: case report and literature review. *Mod Rheumatol Case Rep*. 2024 Oct 23: rxae066.
2. Yoshida M, Iwata S, Tabata K, Hashimoto A, Matsumiya R, Tanaka K, Iwamoto R, Jinnin M, Fujii T. MPO-ANCA-positive eosinophilic granulomatosis with polyangiitis complicated by alveolar hemorrhage treated with

mepolizumab as an induction therapy: Case report. *Mod Rheumatol Case Rep.* 2024 Dec 21. DOI: 10.1093/mrcr/rxae088. PMID: 39707621. in press.

#### 【雑誌】

1. 藤井 隆夫. アダリムマブ皮下注射を導入した非感染性ぶどう膜炎の3症例. *眼科* 66 (9), 927-935. 2024. 金原出版
2. 藤井 隆夫. 混合性結合組織病. *日本臨牀*. 1236-1241. 2024-8. 日本臨牀社 東京
3. 藤井 隆夫. 膠原病 : 抗核抗体は病原性を有するか. *皮膚科*. 6(5). 450-455. 2024-11. 皮膚科編集委員会 編. 東京
4. 岩田 慈, 藤井 隆夫. 特集 ステロイドフリーを目指す膠原病診療. 全身性エリテマトーデス. *リウマチ科*, 72(3):248-254, 2024. リウマチ科編集委員会 編. 科学評論社 東京
5. 岩田 慈, 藤井 隆夫. 特集 リウマチ・膠原病診療で注意すべき日和見感染症. 進行性多巣性白質脳症. *リウマチ科*, 71(1):41-46, 2024
6. 岩田 慈, 藤井 隆夫. 膠原病の概要と疫学. *Medical Practice* 2024 41:186-193 編. 文光堂 東京
7. 岩田 慈, 藤井 隆夫. 関節リウマチat risk者に対するMTXの有効性 —Treat Earlier試験から—. *リウマチ科*, 71(5):531-534, 2024 リウマチ科編集委員会 編. 科学評論社 東京

#### 【書籍】

1. 藤井 隆夫. 関節リウマチに合併するリンパ増殖性疾患～その他の医療性免疫不全関連リンパ増殖性疾患を含め～. 出版. 伊藤理恵、松山綾. *リウマチクリニック*18-19. 2024メディカルレビュー社. 大阪